Retinoic acid inhibits phospholipid turnover and protein kinase C activity in RA-sensitive but not in RA-resistant cells  by Vanier, M.C. et al.
Volume 241, number 1,2, 154-158 FEB 06560 December 1988 
Retinoic acid inhibits phospholipid turnover and protein kinase C 
activity in RA-sensitive but not in RA-resistant cells 
M.C.  Van ier ,  D. Baner jee and  B.B. Mukher jee  
Department of Biology and Centre for Human Genetics, McGill University, 1205 Dr Penfield Ave., Montreal, 
Quebec H3A 1B1, Canada 
Received 12 September 1988; revised version received 6October 1988 
Treatment with I 0 -s M retinoic acid causes loss of anchorage-independent growth in src-transformed RR1022 cells but 
not in ras-transformed KNRK cells. In an effort o elucidate the mechanisms underlying this difference, we investigated 
the effect of RA on phospholipid turnover and PKC activity in these two cell lines. 10 -s M RA treatment caused adrastic 
inhibition of 32P incorporation i to PI and PA and a large increase in32p incorporation i to PC in RRI022 cells. Similar 
treatment ofKNRK cells yielded no change in PC or PA labelling and a much smaller decrease inPI labelling. Further- 
more, 10 -5 M RA treatment causes a large decrease inPKC activity in RRI022 cells (35% of control) but only a small 
decrease inKNRK cells (78% of control). We suggest that hese ffects are part of an altered signal transduction pathway 
which mediates the differential effects of RA on anchorage-independent growth in these two cell ines. 
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1. INTRODUCTION 
It has been clearly established that retinoids 
(vitamin A and its analogues) can cause reversible 
loss of anchorage- independent growth (an ac- 
knowledged marker for oncogenically transformed 
cells) of  a large number  of transformed cell lines of 
diverse origin, as well as intervene in the process of 
oncogenesis n vivo (reviewed in [1,2]). However, 
some transformed cells do not lose their ability to 
form colonies in agar medium upon treatment with 
retinoids [1-4]. It is not known what causes the 
differential response to retinoids by various trans- 
formed cells. Jetten et al. [4] have reported recent- 
ly that Syrian hamster embryo cells transformed by 
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transfection with the v-src oncogene lose 
anchorage- independent growth after treatment 
with RA but RA enhances anchorage-independent 
growth of the same cell line transformed by the v- 
Ha-ras oncogene. Our previous study [3] showed 
that RA inhibits phosphorylat ion of a group of 
low molecular mass plasma membrane proteins 
(LMPs) in RSV-transformed rat (RR1022) cells 
which undergo RA-induced loss of anchorage- 
independent growth (RA-sensitive cells). However, 
RA did not have any effect on the phosphorylat ion 
of LMPs in Ki-ras transformed normal rat kidney 
ceils (KNRK) which also do not lose the ability to 
grow in an anchorage-independent manner  upon 
RA treatment (i.e. they are RA-resistant). 
In this report we provide evidence that RA 
causes a drastic alteration of phospholipid turn- 
over and inhibits activation of the membrane 
associated, Ca 2÷- and phosphol ipid-dependent 
protein kinase (protein kinase C). However, these 
RA-induced effects are either not detectable, or 
not as pronounced in RA-resistant KNRK cells. 
These observations lend further support to the 
hypothesis that activation of different oncogenes 
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in various transformed cells may determine their 
response to retinoids. 
2. MATERIALS  AND METHODS 
2.1. Cells and cell culture 
The Schmidt-Ruppin strain of Rous sarcoma virus (SR-RSV)- 
transformed rat cell line (RR 1022) and Kirsten murine sarcoma 
virus (Ki-MSV)-transformed normal rat kidney cells (KNRK) 
were purchased from the American Type Culture Collection 
(Rockville, MD). Cells were routinely maintained inDulbecco's 
modified Eagle's minimal essential medium (DMEM) sup- 
plemented with 10070 newborn calf serum (Gibco). Stock solu- 
tions (10 -2 M) of RA (all-trans retinoic acid; Sigma) were 
prepared in dimethyl sulfoxide (DMSO) and were diluted with 
DMEM to a final concentration f 10 -5 M. The final concen- 
tration of DMSO was 0.1070; control experiments showed that 
this concentration was not toxic to the cells nor was it responsi- 
ble for the effects ascribed to RA treatment (not shown). 
2.2. Phospholipid analysis 
Cells which were to be analyzed for phospholipid turnover 
were first starved for phosphate by incubating them in 2 ml of 
phosphate- and serum-free DMEM for 1 h prior to labelling. 
The media was changed and the cells were labelled for 2 h with 
100/~Ci of carrier-free [32Plorthophosphate (Amersham) in 
1 ml of phosphate-free DMEM containing no serum. Labelled 
phospholipids were extracted from cells essentially asdescribed 
by Agranoff et al. [5]. Samples were spotted on silica gel G 
plates (Brinkman) and the phospholipids were separated by 
TLC using a solvent system consisting of chloroform/metha- 
nol/acetic acid/water (65:43 : 1:3). Radiolabelled phospho- 
lipids were identified by autoradiography on X-ray film and the 
spots corresponding to the various lipids were scraped from the 
TLC plates and quantitated by liquid scintillation counting. 
2.3. Measurement of protein kinase C activity 
Membrane vesicles were isolated from untreated and RA- 
treated cells according to a procedure described previously [3]. 
Protein kinase C (PKC) was assayed following the procedure 
described by Fearn and King [6]. The reaction mixture (total 
volume 125/zl) contained 50/~g lysine-rich histone, 20 mM Tris- 
HCI, pH 7.5, 0.5 mM CaCh, 75 mM MgCI2, 10,ug aprotinin, 
12 Izg phosphatidylserine (PS), 1 ,ug diolein, and 25,ul mem- 
brane suspension i 0.1 °70 NP40. The reaction was initiated by 
the addition of 20 mM ATP ([7)2P]ATP, Amersham) and in- 
cubated for 3 min at 30°C. The reaction was stopped by the ad- 
dition of 200/tl of 25070 TCA. Precipitates were collected on 
Whatman glass fiber filters and washed extensively with 25°70 
TCA. Control experiments were carried out by omitting Ca 2+, 
diolein, and PS, and adding 10 4 M EGTA. PKC activity is ex- 
pressed as the ratio of radiolabel incorporated into histone in 
Ca2+/PS/diolein-containing reactions over those without. 
3. RESULTS 
3.1. Effect o f  RA treatment on phospholipid 
turnover in RR1022 and KNRK cells 
We have previously shown [3] that RR1022 and 
KNRK cells can grow for extended periods of time 
in the presence of 10 -5 M RA; i.e. this dose is not 
toxic to either cell type. However, RR1022 ceils, 
which form large colonies in suspension in the 
absence of RA, show drastically reduced colony 
format ion in soft agar in the presence of 10 -5 M 
RA, both in terms of size and number  of colonies. 
On the other hand, KNRK cells show no signifi- 
cant change in colony formation upon RA treat- 
ment.  We have established that the mechanism of 
action of RA on anchorage-independent growth is 
membrane-related and is not related to the 
presence of cytosolic RA-binding proteins [7]. 
Therefore, we wished to examine whether phos- 
pholipid metabol ism was affected by RA, and, if 
so, whether the effect was different for RA- 
sensitive and RA-resistant cells. Cells were pre- 
treated with phosphate-free DMEM in the absence 
of label and with or without RA (10 -5 M) for 1 h. 
Then the media was changed and the cells were 
labelled with 32pi for 2 h with or without RA. The 
phospholipids were then extracted and run on un- 
treated TLC plates to separate out the major  
phosphol ipid classes. The results are shown 
graphically in fig. 1. In RR1022 cells, the most pro- 
minent effects of RA treatment on phospholipid 
turnover are: (i) a large increase in the relative 
amount  of label incorporated into PC, from 
25.3°7o to 53.5070 of the total label incorporated in- 
to phospholipid; (ii) a large decrease in the relative 
amount  of label incorporated into PA,  from 
38.707o to 13.5070 of the total; (iii) a significant 
decrease in the relative amount  of label incor- 
porated into PI, from 12.1070 to 5.807o f the total 
label. These results are all statistically significant 
(p < 0.02 for PC and PA,  p < 0.05 for PI; n = 7). 
In contrast, PS and PE showed no significant 
change. As can also be seen in fig. 1, no significant 
changes in the relative amounts of any phos- 
pholipid occurred in KNRK cells. 
3.2. Effect o f  RA (10-5M) on PKC activity in 
RR1022 and KNRK cells 
We have demonstrated here that RA causes 
significant alterations in phospholipid turnover in 
RR1022 cells but not in KNRK cells. Since PIP2 
hydrolysis (as well as that of other phospholipids) 
generates diacylglycerol (DG) which can then ac- 
tivate PKC, and since RA is known to antagonize 
the effects of phorbol ester tumor promotors 
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Fig.1. Effect of RA (10 -5 M) on phospholipid turnover in RR1022 and KNRK cells. Data shown are the average _+ SE of 7 replicates 
for RRI022 cells and 6 replicates for KNRK cells. 
(which activate PKC) in many systems [2], we 
decided to examine PKC activity in untreated and 
RA-treated RR1022 and KNRK cells to see 
whether RA would only antagonize the enzyme's 
effect in RA-sensitive cells (i.e. RR1022). In table 
1, the effect of 24 h treatment of 10 -5 M RA on 
PKC activity in RR1022 and KNRK cells is shown. 
Clearly, RA inhibits PKC activity drastically in 
RR1022 cells (activity about 35°7o f untreated con- 
trols) but little or not at all in KNRK cells (activity 
about 78°70 of untreated controls). It should be 
mentioned that since an exogenous diacylglycerol 
(diolein) as well as phosphatidylserine was added 
to the reaction mixture, the effect of RA on PKC 
activity seen is presumably not mediated directly 
Table 1 
Effect of 10 5 M RA on PKC activity in RR1022 and KNRK 
cells, expressed as the ratio of units (,umol Pi/mg protein per 
rain) determined with PS and DG over units determined without 
PS and DG 
PKC activity ( + DG,PS / -  DG,PS) 
RR1022 2.049 _+ 0.427 
RR1022 + RA 0.707 _+ 0.217 
KNRK 2.774 ± 1.221 
KNRK + RA 2.164 _+ 0.592 
Data shown are average of four experiments + SE 
through its effect on phospholipid turnover (whose 
effect of activating PKC is thought o be mediated 
principally by the production of DG and the 
presence of PS). Rather, it is probable that RA in- 
hibits phospholipid turnover and PKC activity in- 
dependently. 
4. DISCUSSION 
The data presented here clearly show that treat- 
ment of RR1022 cells with 10-SM RA, which 
causes a drastic inhibition of anchorage-indepen- 
dent growth [3], also causes a number of altera- 
tions in phospholipid metabolism. Specifically, 
RA treatment causes a large relative increase in the 
amount of 32pi incorporated into PC and a large 
decrease in the amount of 32pi incorporated into 
PA and PI. The incorporation of label into PS and 
PE is unaffected by RA treatment. However, 
KNRK cells, which do not show reduced an- 
chorage-independent growth upon RA treatment 
[3], show no significant change in PC, PA, and PI 
turnover (fig.l); again, PS and PE are unaffected. 
In addition, RA treatment causes a very large 
decrease in the plasma membrane activity of PKC 
in RR1022 cells but only a small decrease in KNRK 
cells (table 1). This effect is not secondary to the 
effect of RA on phospholipid turnover, since the 
156 
Volume 241, number 1,2 FEBS LETTERS December 1988 
phospholipids or phospholipid breakdown prod- 
ucts (PS and DG) which are required for PKC ac- 
tivation were included in the in vitro reaction 
mixture. Thus it appears that RA inhibits the 
phosphol i id/PKC signal transduction pathway at, 
at least, two separate points. The effect of RA on 
phospholipid turnover represents a very early ef- 
fect of RA; 3 h of RA treatment produces ignifi- 
cant changes in the phospholipid profile of 
RR1022 cells. This is in contrast with many effects 
of retinoids including most of their effects on 
growth and differentiation [1,2] as well as the RA- 
mediated induction or regulation of specific genes 
(e.g. [8-101). 
We do not know the mechanisms by which RA 
exerts these effects on phospholipid turnover and 
PKC activity. It has been shown that RA can in- 
hibit phospholipase C-mediated ornithine decar- 
boxylase induction in rat tracheal cells [11]. It is 
therefore possible that RA inhibits a 
phospholipase C activity and thereby affects phop- 
shoinositide breakdown. Alternatively, RA may be 
inhibiting enzymes involved in the synthesis of 
phospholipids. Much work obviously remains to 
be done in order to establish more clearly the 
mechanisms of RA's effect on phospholipid 
turnover. 
The inhibition of PKC by RA is not surprising 
given that in many cell types retinoids can inhibit 
the tumor-promoting effects of phorbol esters, 
which activate PKC [2]. Retinal has been shown to 
inhibit PKC activity in RAW264 cells [12]. RA has 
also been shown to inhibit PKC activity in mouse 
brain cells [13], which is consistent with our 
results. 
Other reports examining the effects of retinoids 
on phospholipid metabolism have produced results 
differing from those reported here. Lochner et al. 
[14] have demonstrated that al l - t rans-ret inol  ac- 
tivates PI-specific phospholipase C in neutrophils 
and causes only a slight decrease in PKC activity. 
Ponec et al. [15] showed no alteration in phos- 
pholipid turnover at 3 × 10 -6 M RA in squamous 
cell carcinoma cells. Neither report examines the 
relationship between the effect of RA on phospho- 
lipid turnover and its effect on anchorage-inde- 
pendent growth. It is evident that different cell 
types differ in their sensitivity to RA. It is alsc ~aot 
surprising that neutrophils respond differently 
than established transformed cell lines. 
The manner by which KNRK cells escape from 
or mitigate the effects of RA on phospholipid turn- 
over, PKC activity and anchorage-independent 
growth is also not known. It is known that in NRK 
cells (from which KNRK cells are derived) RA can 
enhance the induction of anchorage-independent 
growth by TPA or EGF and TGF-~ [16-18]. 
Therefore, the resistance of KNRK cells to RA's 
effects on phospholipid turnover and PKC activity 
may be partially cell-type specific. In addition, it 
may be that the ras protein of KNRK cells 
somehow confers RA resistance onto the cells. 
Consistent with this view are the findings of Jetten 
et al. [4], who reported that in a syrian hamster 
ovary cell line, transfection with v-src resulted in 
cells in which RA inhibited anchorage-independent 
growth and ODC induction by phorbol esters, 
whereas transfection with v-Ha- ras  resulted in cells 
that showed enhanced anchorage-independent 
growth and phorbol ester-induced ODC activity 
upon RA treatment. 
In conclusion, in the light of these and previous 
observations it can be suggested that RA's effect 
on anchorage-independent growth is mediated by a 
pathway involving phospholipid turnover (in- 
cluding PI turnover) and PKC activation. Further- 
more, the response of a given transformed cell type 
to RA is critically dependent on the nature of the 
cell type and the transforming oncogene. It would 
be of interest to see whether other ras- and src- 
transformed cell lines show similar differential 
responses to RA in terms of anchorage-inde- 
pendent growth, phospholipid turnover, and PKC 
activation. 
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